CA2304981A1 - Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites - Google Patents

Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites Download PDF

Info

Publication number
CA2304981A1
CA2304981A1 CA002304981A CA2304981A CA2304981A1 CA 2304981 A1 CA2304981 A1 CA 2304981A1 CA 002304981 A CA002304981 A CA 002304981A CA 2304981 A CA2304981 A CA 2304981A CA 2304981 A1 CA2304981 A1 CA 2304981A1
Authority
CA
Canada
Prior art keywords
rho
growth
rho family
family members
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304981A
Other languages
English (en)
Inventor
Lisa Mckerracher
Maxime Lehmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002304981A priority Critical patent/CA2304981A1/fr
Publication of CA2304981A1 publication Critical patent/CA2304981A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne l'utilisation d'antagonistes de Rho, ou de protéines apparentées à Rho en tant que cibles thérapeutiques pour des agents conçus pour bloquer l'inhibition de la croissance par la myéline ou des protéines myéliniques. Un mode de réalisation a trait à l'utilisation d'antagonistes de Rho développant la régénération des axones dans le système nerveux central. L'agent ou l'antagoniste thérapeutique peut se présenter sous la forme de petites molécules, protéines ou peptides, ou n'importe quel agent se liant à Rho ou aux membres de sa famille pour inactiver cette voie. On peut citer parmi les modes de réalisation l'utilisation de la voie régulatrice de Rho en tant que cible d'antagonistes de Rho; l'utilisation d'inhibiteurs de dissociation de GDP (GDI) inhibe la dissociation de GDP de Rho, et par conséquent empêche la liaison de GDP nécessaire à l'activation de Rho; l'utilisation d'une protéine d'activation de GTPase (GAP) spécifique de Rho en tant que cibles pour régulation de l'activité de Rho; l'utilisation d'agents stimulant la liaison de Rho à GDI et bloquant la liaison de Rho à la membrane du plasma est également considérée comme faisant partie de cette invention; l'utilisation de C3 transférase et de toxines apparentées telles que A et B, présentant une activité inhibitrice de Rho apparentée destinée à inactiver Rho et à stimuler la croissance des axones; et l'utilisation de formes négative dominantes de Rho, pour inactiver Rho, afin de développer la croissance des axones.
CA002304981A 1997-10-31 1998-11-02 Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites Abandoned CA2304981A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002304981A CA2304981A1 (fr) 1997-10-31 1998-11-02 Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002214841A CA2214841A1 (fr) 1997-10-31 1997-10-31 Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites
CA2,214,841 1997-10-31
CA002304981A CA2304981A1 (fr) 1997-10-31 1998-11-02 Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites
PCT/CA1998/001013 WO1999023113A2 (fr) 1997-10-31 1998-11-02 Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites

Publications (1)

Publication Number Publication Date
CA2304981A1 true CA2304981A1 (fr) 1999-05-14

Family

ID=4161412

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002214841A Withdrawn CA2214841A1 (fr) 1997-10-31 1997-10-31 Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites
CA002304981A Abandoned CA2304981A1 (fr) 1997-10-31 1998-11-02 Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002214841A Withdrawn CA2214841A1 (fr) 1997-10-31 1997-10-31 Les antagonistes rho et leurs utilisations pour arreter l'inhibition d'excroissance d'axone et des dendrites

Country Status (4)

Country Link
EP (1) EP1049715A2 (fr)
AU (1) AU9732198A (fr)
CA (2) CA2214841A1 (fr)
WO (1) WO1999023113A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141428B2 (en) 2000-11-02 2006-11-28 Mckerracher Lisa Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
WO2008077236A1 (fr) * 2006-12-22 2008-07-03 Bioaxone Therapeutique Inc. Protéines variantes de fusion d'adp-ribosyl transférase
US7572913B2 (en) 2004-02-24 2009-08-11 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
US7910554B2 (en) 2001-04-12 2011-03-22 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
US9687483B2 (en) 2015-01-26 2017-06-27 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03002410A (es) 2000-09-20 2003-06-19 Merck Patent Gmbh 4-amino-quinazolinas.
CN101310771B (zh) * 2001-04-11 2012-08-08 千寿制药株式会社 视觉功能障碍改善剂
CA2367636C (fr) 2001-04-12 2010-05-04 Lisa Mckerracher Proteines de fusion
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
WO2003030836A2 (fr) 2001-10-12 2003-04-17 Case Western Reserve University Regeneration neuronale
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
WO2003062227A1 (fr) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Inhibiteurs de kinase rho
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
CA2513584A1 (fr) * 2003-01-20 2004-08-05 Vib Vzw Utilisation de proteines yop ou d'inhibiteurs rho gtpase comme inhibiteurs de caspase-1
CN101340912A (zh) 2005-12-22 2009-01-07 爱尔康研究有限公司 用于治疗rho激酶介导的疾病和病状的(吲唑-5-基)-吡嗪和(1,3-二氢-吲哚-2-酮)-吡嗪
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
EP2177218A1 (fr) * 2008-10-15 2010-04-21 Medizinische Universität Wien Thérapie régénératrice

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005723A1 (fr) * 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
WO1997018303A1 (fr) * 1995-11-16 1997-05-22 Novartis Ag Proteine kinase rac utile en tant qu'agent therapeutique ou dans des diagnostics
US6060297A (en) * 1997-04-17 2000-05-09 Incyte Pharmaceuticals, Inc. Rho protein
WO1999008533A1 (fr) * 1997-08-13 1999-02-25 Yale University Regeneration d'axones dans le systeme nerveux central

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141428B2 (en) 2000-11-02 2006-11-28 Mckerracher Lisa Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
US7491692B2 (en) 2000-11-02 2009-02-17 Mckerracher Lisa Methods for making and delivering Rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
US7910554B2 (en) 2001-04-12 2011-03-22 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
US7572913B2 (en) 2004-02-24 2009-08-11 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
WO2008077236A1 (fr) * 2006-12-22 2008-07-03 Bioaxone Therapeutique Inc. Protéines variantes de fusion d'adp-ribosyl transférase
EP2407536A1 (fr) 2006-12-22 2012-01-18 Bioaxone Therapeutique Inc. Protéines variantes de fusion d'ADP-ribosyl transférase
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US9687483B2 (en) 2015-01-26 2017-06-27 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10526313B2 (en) 2015-01-26 2020-01-07 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US11701366B2 (en) 2015-01-26 2023-07-18 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US11814361B2 (en) 2016-12-21 2023-11-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease

Also Published As

Publication number Publication date
AU9732198A (en) 1999-05-24
WO1999023113A2 (fr) 1999-05-14
CA2214841A1 (fr) 1999-04-30
WO1999023113A3 (fr) 1999-08-26
EP1049715A2 (fr) 2000-11-08

Similar Documents

Publication Publication Date Title
CA2304981A1 (fr) Antagonistes de la famille rho et leur utilisation pour bloquer l'inhibition de l'excroissance des neurites
US20070128585A1 (en) (+)-trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
Duclert et al. Acetylcholine receptor gene expression at the developing neuromuscular junction.
AU769166B2 (en) Fizz proteins
US7544654B2 (en) ψεRACK peptide composition and method for protection against tissue damage due to ischemia
US8906363B2 (en) Fusion proteins for the treatment of CNS
JP2009102392A (ja) プロテインキナーゼｃのペプチドインヒビター
KR20050110012A (ko) 노고 수용체 결합 단백질
Turley et al. Astrocyte and microglial motility in vitro is functionally dependent on the hyaluronan receptor RHAMM
EP2354155B1 (fr) Protéines de fusion pour le traitement du SNC
US6982170B1 (en) Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
Terada et al. Inhibition of excitatory neuronal cell death by cell‐permeable calcineurin autoinhibitory peptide
US7732206B2 (en) Oligodendrocyte determination genes and uses thereof
US6635616B2 (en) Laminin 15
US20050255543A1 (en) Enzyme-deficient c3 botulinum protein species and their use to promote neuronal growth and neuronal regeneration
JP2004508827A (ja) カルシウム結合タンパク質
JP2007511210A (ja) 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法
US20080233098A1 (en) RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
US20030211141A1 (en) Genetic and protein manipulation of betaIG-H3 for the treatment and cure of muscular dystrophies
AU2014265113B2 (en) Fusion proteins for the treatment of cns
EDGAR 11. LAMININS DURING NEURITE GROWTH AND NERVE REGENERATION
Shaw Functional analysis of the Neurofibromatosis Type II tumor suppressor gene
Borisoff Intrinsic neuronal determinants of neurite regrowth
CA2482589A1 (fr) Compositions et methodes de traitement de la maladie d'alzheimer
JP2003334083A (ja) 新規アペリン受容体およびそのｄｎａ

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead